Clinical Trial Update: Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update reports results for Abemaciclib (Verzenio) in men with heavily treated metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-05-24